• SARS-CoV-2 Nucleocapsid LLPS and GCG

  2026-09-21

  The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral biology and shows that the green-tea polyphenol GCG can disrupt this condensation. Its combination of computational screening, variant analysis, biophysical assays, and infection experiments provides a framework for studying condensate-directed antiviral strategies.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-21

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled investigation of mTORC1 and mTORC2 signaling in biochemical, cellular, cancer, and metabolic research. It is appropriate for preclinical pathway studies, but its water insolubility, limited clinical benefit, and lack of directly matched paper evidence in this brief mean it should not be used to support clinical efficacy or unvalidated aqueous dosing conclusions.

• GCG Disrupts SARS-CoV-2 Nucleocapsid Condensation

  2026-09-20

  The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic feature of viral replication and assembly. It further shows that the green-tea polyphenol GCG disrupts N condensation and suppresses viral replication, establishing a framework for studying antiviral intervention at biomolecular condensates.

• Macrophage EV miR-660 in Breast Cancer Metastasis

  2026-09-19

  The reference study identifies a macrophage-to-tumor communication pathway in which extracellular-vesicle miR-660 targets KLHL21 and activates IKKβ/NF-κB p65 signaling, thereby promoting breast cancer cell migration, invasion, and metastatic spread. Its tissue, cell, extracellular-vesicle, and mouse-model evidence provides a useful framework for studying how tumor-associated macrophages reshape cancer behavior.

• AST 487 KDM4A Assay Workflows in MPM

  2026-09-18

  Use AST 487 as a pharmacological probe to test KDM4A-dependent growth, apoptosis, and DNA-repair vulnerabilities in malignant pleural mesothelioma models. This guide connects target validation with dose finding, orthogonal controls, combination screens, and troubleshooting without treating exploratory assay conditions as clinical recommendations.

• GDC-0994: ERK1/2 Inhibitor Workflow Guide

  2026-09-18

  Build reproducible ERK1/2 inhibition experiments with GDC-0994 across BRAFV600E and KRAS-mutant cancer models and zebrafish cholestasis assays. This guide links short-term ERK phosphorylation inhibition to longer-term tumor cell proliferation suppression and bile-acid transport phenotypes, with practical controls for solvent, exposure, and assay interpretation.

• Nocodazole for Microtubule Entry Assays

  2026-09-17

  Nocodazole provides reversible control over microtubule assembly, making it useful for separating cytoskeletal trafficking from clathrin-mediated uptake in infection models. This article translates the S2-cell Spiroplasma study into practical dose selection, controls, troubleshooting, and broader applications in cell-cycle and cancer research.

• PP 1: A Causal Probe of Src Kinase Signaling

  2026-09-17

  PP 1 is a selective Src family tyrosine kinase inhibitor for separating Lck, Fyn, Lyn, and RET-linked signaling from broader pathway effects. This article explains how to deploy PP 1 as a mechanistic assay tool while applying lessons from chemoproteomics and genetic validation in kinase research.

• (-)-Arctigenin in EV–NF-κB Assays

  2026-09-16

  Use (-)-Arctigenin as a dose-controlled pharmacological probe for LPS- and macrophage-EV-driven inflammatory signaling in breast cancer models. Its complementary MEK1 and NF-κB activity supports pathway triangulation, while careful solubility, vehicle, and EV controls help separate signaling effects from nonspecific cytotoxicity.

• p-Cresyl Sulfate: A Compartment-Aware Research Guide

  2026-09-16

  Explore how p-Cresyl sulfate, or p-tolyl hydrogen sulfate, can be used to connect uremic exposure with endothelial and biliary injury. This guide translates product chemistry and recent mechanistic evidence into better-controlled assays for cardiovascular, renal, and hepatobiliary research.

• AU-24118 and ABCB1 Resistance in Prostate Cancer

  2026-09-15

  This PNAS study introduces AU-24118, an orally bioavailable PROTAC degrader of mSWI/SNF ATPase components, and demonstrates tumor regression in preclinical castration-resistant prostate cancer models. It also identifies SMARCA4 mutations and ABCB1 overexpression as distinct acquired resistance mechanisms, with the ABCB1 inhibitor Zosuquidar restoring sensitivity to several PROTAC classes.

• Imatinib (STI571) Workflows for Kinase Research

  2026-09-15

  Build reproducible kinase-inhibition, proliferation, and differentiation assays with Imatinib (STI571), while separating pathway blockade from changes in kinase abundance. The workflow also shows how to use imatinib alongside the hypoxia-driven erythroid model reported in recent erythroleukemia research.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-14

  The reference study identifies ATRX loss as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its results also support evaluating RTK inhibitor–temozolomide combinations in an ATRX-aware manner, while emphasizing that genotype-stratified interpretation is essential for translational cancer research.

• PF-573228 FAK Inhibitor Workflow

  2026-09-14

  PF-573228 provides a practical way to test how FAK links matrix stiffness, focal adhesion signaling, migration, survival, and angiogenesis. This workflow translates dentinogenesis findings into controlled mechanobiology, cancer-cell motility, and endothelial assays with dose-aware troubleshooting.

• SAN-Plexus Assembloids Reveal Pacemaker Maturation

  2026-09-13

  This study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac ganglionated plexus, and atrial-like tissues to model neural control of pacemaker maturation and conduction. Integrated electrophysiology and human SAN spatial transcriptomics identify a prosaposin–GPR37 signaling axis as a candidate mechanism linking cardiac neurons with pacemaker development.

8481 records 1/566 page Next 12345 下5页 Last page